Systemic lupus erythematosus: causes and manifestations

Little is known about the precise aetiology of systemic lupus erythematosus, but treatment should be individualised according to predominant symptoms, organ involvement, response to previous therapy and disease activity and severity.
Source: Trends in Urology and Men's Health - Category: Urology & Nephrology Authors: Tags: Rheumatology Source Type: research

Related Links:

Authors: Zheng CZ, Yan WW, Luo YL, Wang TL, Shu YB Abstract OBJECTIVE: To explore whether Soluble tumor necrosis factor-receptor 1 (sTNF-R1) and linc0597 can be used as indicators for disease activity and diagnosis of lupus nephritis (LN). PATIENTS AND METHODS: Eighty LN patients treated in our hospital were enrolled as the LN group, while 60 Systemic Lupus Erythematosus (SLE) patients without nephritis were included in the SLE group, and 50 healthy subjects who conducted physical examination during the same period as the control group. After admission, 5 mL of venous blood was taken from all the study subjects...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
This study focused on the regulation of IFNAR expression in macrophages.MethodsWe carried out gene expression profiling of purified CM and NCM from mice treated with pristane (develop lupus) or mineral oil (MO, non ‐lupus control). Macrophage differentiation and IFNAR expression were examined in mice treated with Nrf2 activators and inhibitors and in Nrf2‐deficient mice. Nrf2 activity also was assessed in blood cells from SLE patients.ResultsRNA ‐sequencing analysis revealed increased expression of genes regulated by the transcription factor Nrf2 in NCM from MO‐ vs. pristane‐treated mice and in NCM vs. CM. The Nr...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
A Peninsula company spun out of Amgen Inc. after its acquisition of Onyx Pharmaceuticals saw its stock climb 73% Thursday on results from a study of its lead drug in people with a type of lupus. Kezar Life Sciences Inc. (NASDAQ: KZR) said people given the drug, called KZR-616, showed improvements across seven measures of disease activity in a Phase Ib study in systemic lupus erythematosus, a disease in which the immune system attacks healthy tissue and affects the skin, joins, kidneys, br ain and…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Conclusions: The present data suggest that CT and TT genotypes of OPN 707 C/T SNP are associated with a higher SLE risk, but do not affect the clinical course of the disease in the Polish population. PMID: 32489353 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Authors: Leisenring NH, Rogers JL, Telloni S, Mansoori P, Al-Rohil RN, Marano AL Abstract Novel oral anticoagulant (NOAC) medications have revolutionized hematology and cardiology. Recently, NOACs have demonstrated additional promise in dermatology. Specifically, rivaroxaban, a direct factor Xa inhibitor NOAC, has been shown to be successful in the treatment of livedoid vasculopathy. Herein, we describe a patient with systemic lupus erythematosus who presented with painful cutaneous vasculopathy, demonstrated on biopsy with occlusive microvascular fibrin thrombi without evidence of concurrent vasculitis. Interestin...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
The objective of this study is to investigate the risk of non-melanoma skin cancer in patients with connective tissue disease and to assess the impact of immunosuppressive therapy on this risk. This is a retrospective case control cohort study of 8281 patients with connective tissue disease (systemic lupus erythematosus, Sjogren’s disease and scleroderma) and 8281 age, race, and gender matched controls followed for a 5-year period between 2002-2012, who obtained their care from a large integrated multispecialty group practice in Northern California. The odds ratio for developing squamous cell skin cancer among patien...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
On June 3, the World Health Organization (WHO) resumed a study looking into whether the malaria drug hydroxychloroquine could be effective in treating COVID-19. Last week, the WHO temporarily stopped people from enrolling in the trial, part of a larger study called Solidarity that is investigating a number of different potential coronavirus therapies, over concerns about the hydroxychloroquine’s adverse effects on the heart. That followed the publication of a Lancet study on May 22, involving more than 96,000 people, which found that the drug did not improve survival among patients hospitalized with COVID-19, and tha...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
In conclusion, we report the case of tunneled hemodialysis catheter-related complete obstruction of the right brachiocephalic vein in a lupus nephritis patient undergoing hemodialysis. Clinicians should be aware of this potential complication when tunneled hemodialysis catheters are used and consider the next vascular access type before a tunneled hemodialysis catheter has been indwelled for the long term. PMID: 32484005 [PubMed - as supplied by publisher]
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
AbstractPurpose of ReviewUpdate on the diagnosis, treatment, and monitoring of lupus nephritis.Recent FindingsThe recent criteria enable the earlier classification of lupus nephritis based on kidney biopsy and compatible serology. Treatment of active nephritis includes low-dose intravenous cyclophosphamide or mycophenolate, followed by maintenance immunosuppression. Recent trials have suggested superiority of regimens combining mycophenolate with either calcineurin inhibitor or belimumab, although their long-term benefit/risk ratio has not been determined. Encouraging results with novel anti-CD20 antibodies confirm the eff...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
WEDNESDAY, June 3, 2020 -- More than one-third of patients with lupus have experienced significant issues filling their hydroxychloroquine prescription during the COVID-19 pandemic, according to the results of a survey released May 28 by the Lupus...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Lupus | Rheumatology | Urology & Nephrology